NCT05191784

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

A Phase 2, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Genexine, Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.

Detailed description

This is a phase 2 study designed to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma. A total of 20 patients will be enrolled in the study and administered bevacizumab GX-I7. The study treatment will be continued for up to 6 cycles or until a progression of disease or unacceptable toxicity is confirmed.

Conditions

• Recurrent Glioblastoma

Interventions

Type	Name	Description
DRUG	GX-I7	Administered by intramuscular (IM) injection
DRUG	Bevacizumab	Administered by intravenous (IV) injection

Timeline

• Start date: 2022-01-26
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2022-01-13
• Last updated: 2023-06-12

Locations

1 site across 1 country: South Korea